Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TVTX

Travere Therapeutics Inc

Dec 11 • 04:00PM ET

18.68

Dollar change -0.07
Percentage change -0.37	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI IWM VXF XBI IWN IBB PJP SCHA VTWO DWAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.56	Insider Own	1.52%	Shs Outstand	87.03M	Perf Week	-3.56%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-1.19	Insider Trans	-8.95%	Shs Float	85.74M	Perf Month	-1.84%
Income	-351.52M	PEG	-	EPS next Q	-0.64	Inst Own	97.31%	Short Float	8.83%	Perf Quarter	48.25%
Sales	203.45M	P/S	7.99	EPS this Y	-162.28%	Inst Trans	-6.69%	Short Ratio	4.27	Perf Half Y	154.50%
Book/sh	-0.39	P/B	-	EPS next Y	69.70%	ROA	-52.19%	Short Interest	7.57M	Perf Year	115.70%
Cash/sh	3.19	P/C	5.86	EPS next 5Y	-	ROE	-279.94%	52W Range	5.12 - 20.33	Perf YTD	107.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.34%	ROI	-117.93%	52W High	-8.12%	Beta	0.69
Dividend TTM	-	Quick Ratio	1.68	Sales past 5Y	3.07%	Gross Margin	73.91%	52W Low	264.84%	ATR (14)	0.86
Dividend Ex-Date	-	Current Ratio	1.71	EPS Y/Y TTM	-3.48%	Oper. Margin	-137.48%	RSI (14)	53.05	Volatility	4.08% 4.23%
Employees	380	Debt/Eq	-	Sales Y/Y TTM	-2.96%	Profit Margin	-172.78%	Recom	1.27	Target Price	27.40
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	28.50%	Payout	-	Rel Volume	0.45	Prev Close	18.75
Sales Surprise	3.33%	EPS Surprise	-4.62%	Sales Q/Q	69.56%	Earnings	Oct 31 BMO	Avg Volume	1.77M	Price	18.68
SMA20	0.48%	SMA50	4.64%	SMA200	72.08%	Trades		Volume	792,544	Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28
Sep-21-22	Initiated	Bryan Garnier	Sell	$17
Jul-14-22	Resumed	Canaccord Genuity	Buy	$49 → $42
Mar-31-22	Initiated	Piper Sandler	Overweight	$42

Show Previous Ratings

Dec-03-24 05:51AM	Japan MHLW grants orphan drug status to Renalys' sparsentan for IgAN treatment (Pharmaceutical Business Review)
Nov-25-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-12-24 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Nov-07-24 09:05PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +12.40%
04:01PM	Loading…
04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 03:05AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
Oct-31-24 07:00AM	Travere Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-30-24 09:13AM	Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-28-24 08:35AM	Travere presents data reinforcing clinical benefit of FILSPARI in IgAN (TipRanks)
Oct-26-24 07:01AM	Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 (GlobeNewswire)
Oct-21-24 04:30PM	Travere Therapeutics to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-17-24 07:01AM	Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (GlobeNewswire)
02:30AM	Loading…
02:30AM	CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Oct-14-24 04:30PM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +6.28%
Oct-09-24 03:50PM	Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +15.65%
08:02AM	Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales (Insider Monkey)
Sep-26-24 04:01PM	Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up (GlobeNewswire) -6.85%
Sep-12-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.98%
Sep-10-24 04:01PM	Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire) +10.57%
Sep-05-24 05:34PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (GlobeNewswire)
Aug-22-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 (GlobeNewswire)
Aug-06-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.39%
Aug-01-24 04:01PM	Travere Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 04:30PM	Travere Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-10-24 08:43AM	Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength? (Zacks)
Jul-08-24 04:30PM	Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire) +10.52% +8.83%
07:32AM	Loading…
Jun-24-24 07:32AM	Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar? (Zacks) +6.57%
Jun-11-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-09-24 04:30PM	Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress (GlobeNewswire)
May-08-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Travere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ... (GuruFocus.com)
May-06-24 08:59PM	TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:30PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings (Zacks)
05:10PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:30PM	Travere Therapeutics to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 07:05AM	Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (GlobeNewswire) -5.05%
03:00AM	CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Apr-04-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International (GlobeNewswire)
Apr-03-24 04:30PM	Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association (GlobeNewswire)
Mar-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.16% -7.61%
Mar-11-24 07:05AM	Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire) -7.74%
Feb-26-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 07:05AM	Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy (GlobeNewswire)
02:00AM	CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy (PR Newswire)
Feb-16-24 09:52AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.18%
Feb-15-24 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +5.94%
Feb-08-24 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-01-24 04:30PM	Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-25-24 04:05PM	Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations (GlobeNewswire) -6.01%
Jan-08-24 07:00AM	Travere Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire) +13.66%
Jan-02-24 04:30PM	Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.34%
Dec-14-23 07:30AM	Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) (GlobeNewswire)
Dec-04-23 04:05PM	Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS (GlobeNewswire) +17.65%
Nov-21-23 04:30PM	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-23 06:26PM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript (Insider Monkey) -14.06%
Nov-07-23 04:01PM	Travere Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire) +8.13% -11.84%
Nov-03-23 10:46AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire) +5.93%
Oct-24-23 04:30PM	Travere Therapeutics to Report Third Quarter 2023 Financial Results (GlobeNewswire) -5.43%
Oct-13-23 04:30PM	Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.31%
Sep-26-23 04:30PM	Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) (GlobeNewswire) +5.96%
Sep-22-23 09:38AM	Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls (The Fly)
Sep-21-23 07:30AM	Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan (GlobeNewswire) -40.68%
Sep-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-31-23 04:30PM	Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference (GlobeNewswire) +8.26%
Aug-24-23 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (GlobeNewswire)
Aug-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 06:03AM	News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts (Simply Wall St.)
Aug-03-23 04:01PM	Travere Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 12:28PM	J.P. Morgan Recommends These 2 Strong Buy Stocks Including One With 90% Upside Potential (TipRanks)
Jul-20-23 04:30PM	Travere Therapeutics to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-08-23 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 (GlobeNewswire) -7.39%
Jun-01-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 07:00AM	Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +9.02%
May-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-23 04:01PM	Travere Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire) +5.20%
May-01-23 04:05PM	Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (GlobeNewswire) -30.78%
Apr-26-23 04:30PM	Travere Therapeutics to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-23 04:30AM	Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 (GlobeNewswire)
Mar-28-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.68%
Mar-23-23 04:30PM	Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 (GlobeNewswire)
Mar-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 (GlobeNewswire)
Mar-03-23 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-28-23 10:36PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Option Exercise	12.67	15,000	190,050	67,017	Nov 25 09:00 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 25 '24	Sale	18.30	12,090	221,258	54,927	Nov 25 09:00 PM
Calvin Sandra	Officer	Nov 25 '24	Proposed Sale	18.30	12,090	221,258		Nov 25 05:59 PM
LYONS GARY A	Director	Oct 04 '24	Option Exercise	10.48	40,000	419,200	91,000	Oct 04 07:15 PM
LYONS GARY A	Director	Oct 04 '24	Sale	14.73	40,000	589,101	51,000	Oct 04 07:15 PM
GARY A LYONS	Officer	Oct 04 '24	Proposed Sale	13.65	40,000	546,000		Oct 04 04:21 PM
Meckler Jeffrey A	Director	Sep 30 '24	Option Exercise	10.48	40,000	419,200	121,000	Sep 30 08:38 PM
Meckler Jeffrey A	Director	Sep 30 '24	Sale	14.06	40,000	562,324	81,000	Sep 30 08:38 PM
JEFFREY MECKLER	Director	Sep 30 '24	Proposed Sale	14.06	40,000	562,324		Sep 30 04:22 PM
Calvin Sandra	Officer	Sep 11 '24	Proposed Sale	14.80	15,000	222,000		Sep 11 06:29 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Sep 10 '24	Sale	12.98	684	8,878	61,949	Sep 10 04:05 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Sep 09 '24	Sale	11.52	4,387	50,538	84,455	Sep 09 09:20 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Sep 09 '24	Sale	11.52	4,387	50,538	78,633	Sep 09 09:20 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 09 '24	Sale	11.52	21,125	243,360	361,975	Sep 09 09:20 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Sep 09 '24	Sale	11.52	2,191	25,240	62,633	Sep 09 09:20 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Sep 09 '24	Sale	11.52	2,191	25,240	107,958	Sep 09 09:20 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 09 '24	Sale	11.52	2,490	28,685	74,595	Sep 09 09:20 PM
REED ELIZABETH E	Officer	Sep 09 '24	Proposed Sale	11.52	4,387	50,538		Sep 09 10:54 AM
ROTE WILLIAM E.	Officer	Sep 09 '24	Proposed Sale	11.52	4,387	50,538		Sep 09 10:35 AM
Dube Eric M	Officer	Sep 09 '24	Proposed Sale	11.52	21,125	243,360		Sep 09 10:34 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '24	Sale	9.51	514	4,888	70,335	Sep 05 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	6.74	54	364	70,849	Apr 12 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	8.70	19,122	166,435	350,600	Feb 02 04:06 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 01 '24	Sale	8.71	4,764	41,495	80,720	Feb 02 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 01 '24	Sale	8.53	2,820	24,058	52,017	Feb 02 04:05 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 01 '24	Sale	8.71	4,764	41,495	76,270	Feb 02 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 01 '24	Sale	8.53	4,195	35,789	99,503	Feb 02 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	8.53	2,174	18,547	58,074	Feb 02 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	8.53	3,818	32,573	70,903	Feb 02 04:05 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 23 '24	Sale	8.96	2,062	18,476	56,034	Jan 25 04:10 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	8.96	7,873	70,542	234,722	Jan 25 04:10 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 23 '24	Sale	9.07	853	7,735	49,721	Jan 25 04:10 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 23 '24	Sale	8.96	2,062	18,476	60,484	Jan 25 04:10 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 23 '24	Sale	9.07	910	8,252	41,337	Jan 25 04:10 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 23 '24	Sale	9.07	1,559	14,138	78,698	Jan 25 04:10 PM
Inrig Jula	Chief Medical Officer	Jan 03 '24	Sale	9.48	2,069	19,613	35,688	Jan 05 04:11 PM
Inrig Jula	Chief Medical Officer	Jan 04 '24	Sale	9.17	440	4,035	35,248	Jan 05 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience